152 related articles for article (PubMed ID: 12616105)
1. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer.
Crombet T; Torres L; Neninger E; Catalá M; Solano ME; Perera A; Torres O; Iznaga N; Torres F; Pérez R; Lage A
J Immunother; 2003; 26(2):139-48. PubMed ID: 12616105
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
3. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients.
Crombet T; Osorio M; Cruz T; Roca C; del Castillo R; Mon R; Iznaga-Escobar N; Figueredo R; Koropatnick J; Renginfo E; Fernández E; Alvárez D; Torres O; Ramos M; Leonard I; Pérez R; Lage A
J Clin Oncol; 2004 May; 22(9):1646-54. PubMed ID: 15117987
[TBL] [Abstract][Full Text] [Related]
4. [Phase II clinical trial of h-R3 combined radiotherapy for locoregionally advanced nasopharyngeal carcinoma].
Wu RR; Wu SX; Zhao C; Xie FY; Gao JM; Hu WH; Gao YH; Li FY; Cui TT; Lu TX
Ai Zheng; 2007 Aug; 26(8):874-9. PubMed ID: 17697551
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin.
Torres LA; Perera A; Batista JF; Hernández A; Crombet T; Ramos M; Neninger E; Pérez M; Sánchez EL; Romero S; Aguilar V; Coca MA; Iznaga-Escobar N
Nucl Med Commun; 2005 Dec; 26(12):1049-57. PubMed ID: 16264350
[TBL] [Abstract][Full Text] [Related]
7. Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats.
Navarro BG; Parada AC; Alvarez P; Leon A; Santana E; Bada A; Figueredo R; Iznaga-Escobar N; Perez R
Exp Toxicol Pathol; 2005 Mar; 56(4-5):313-9. PubMed ID: 15816360
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: part II. Pharmacokinetics and clearances.
Iznaga-Escobar N; Torres Arocha LA; Morales Morales A; Ramos Suzarte M; Rodríguez Mesa N; Pérez Rodríguez R
J Nucl Med; 1998 Nov; 39(11):1918-27. PubMed ID: 9829584
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of 99mTc-labeled anti-human epidermal growth factor receptor (EGF-R) humanized monoclonal antibody h-R3 in a xenograft model of human lung adenocarcinoma.
Morales-Morales A; Ducongé J; Caballero-Torres I; Núñez-Gandolff G; Fernández E; Iznaga-Escobar N
Nucl Med Biol; 1999 Apr; 26(3):275-9. PubMed ID: 10363798
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.
Iznaga Escobar N; Morales AM; Ducongé J; Torres IC; Fernández E; Gómez JA
Nucl Med Biol; 1998 Jan; 25(1):17-23. PubMed ID: 9466357
[TBL] [Abstract][Full Text] [Related]
11. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
Ramos TC; Figueredo J; Catala M; González S; Selva JC; Cruz TM; Toledo C; Silva S; Pestano Y; Ramos M; Leonard I; Torres O; Marinello P; Pérez R; Lage A
Cancer Biol Ther; 2006 Apr; 5(4):375-9. PubMed ID: 16575203
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study.
Crombet T; Torres O; Rodríguez V; Menéndez A; Stevenson A; Ramos M; Torres F; Figueredo R; Veitía I; Iznaga N; Pérez R; Lage A
Hybridoma; 2001 Apr; 20(2):131-6. PubMed ID: 11394532
[TBL] [Abstract][Full Text] [Related]
13. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.
Faillot T; Magdelénat H; Mady E; Stasiecki P; Fohanno D; Gropp P; Poisson M; Delattre JY
Neurosurgery; 1996 Sep; 39(3):478-83. PubMed ID: 8875477
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of 99mTc-hR3 (DiaCIM), a humanized immunoconjugate directed towards the epidermal growth factor receptor.
Vallis KA; Reilly RM; Chen P; Oza A; Hendler A; Cameron R; Hershkop M; Iznaga-Escobar N; Ramos-Suzarte M; Keane P
Nucl Med Commun; 2002 Dec; 23(12):1155-64. PubMed ID: 12464779
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
18. [Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma].
Huang XD; Yi JL; Gao L; Xu GZ; Jin J; Yang WZ; Lu TX; Wu SX; Wu RR; Hu WH; Xie WC; Han F; Gao YH; Gao JM; Pan JJ; Chen CB; Lang JY; Li T; Dong Y; Fu YB; Fan L; Li BS; Li J; Wang XH; Chen BX; Gao XS; Zhang P; Wu XW; Hu BQ
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):197-201. PubMed ID: 17649636
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.
Wang C; He X; Zhou B; Li J; Li B; Qian W; Hou S; Wang H; Shi Y; Guo Y
MAbs; 2011; 3(1):67-75. PubMed ID: 21051930
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
